These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9485067)

  • 1. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
    Antonini A; Leenders KL; Eidelberg D
    Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography.
    Künig G; Leenders KL; Sanchez-Pernaute R; Antonini A; Vontobel P; Verhagen A; Günther I
    Ann Neurol; 2000 May; 47(5):644-8. PubMed ID: 10805336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntington's disease progression. PET and clinical observations.
    Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
    Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
    Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ
    Brain; 1995 Jun; 118 ( Pt 3)():689-96. PubMed ID: 7600086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
    Weeks RA; Piccini P; Harding AE; Brooks DJ
    Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D2 receptor binding in dopa-responsive dystonia.
    Künig G; Leenders KL; Antonini A; Vontobel P; Weindl A; Meinck HM
    Ann Neurol; 1998 Nov; 44(5):758-62. PubMed ID: 9818931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
    J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates.
    Brandt J; Folstein SE; Wong DF; Links J; Dannals RF; McDonnell-Sill A; Starkstein S; Anders P; Strauss ME; Tune LE
    J Neuropsychiatry Clin Neurosci; 1990; 2(1):20-7. PubMed ID: 1983772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
    Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
    Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.
    van Oostrom JC; Dekker M; Willemsen AT; de Jong BM; Roos RA; Leenders KL
    Eur J Neurol; 2009 Feb; 16(2):226-31. PubMed ID: 19138335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.
    Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; Dunnett SB; Piccini P
    Brain; 2003 May; 126(Pt 5):1127-35. PubMed ID: 12690052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bradykinesia in early Huntington's disease.
    Sánchez-Pernaute R; Künig G; del Barrio Alba A; de Yébenes JG; Vontobel P; Leenders KL
    Neurology; 2000 Jan; 54(1):119-25. PubMed ID: 10636136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene.
    Squitieri F; Esmaeilzadeh M; Ciarmiello A; Jankovic J
    Mov Disord; 2011 Apr; 26(5):925-7. PubMed ID: 21370274
    [No Abstract]   [Full Text] [Related]  

  • 17. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.
    van Oostrom JC; Maguire RP; Verschuuren-Bemelmans CC; Veenma-van der Duin L; Pruim J; Roos RA; Leenders KL
    Neurology; 2005 Sep; 65(6):941-3. PubMed ID: 16186542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease: the relationship between clinical signs, CAG repeats and the atrophy of the caudate nucleus in CT scans.
    Roth J; Zidovská J; Růzicková S; Havrdová E; Preiss M; Uhrová T; Línek V; Doubek P; Volfová M; Jech R; Bauer J; Růzicka E
    Sb Lek; 1999; 100(1):39-44. PubMed ID: 10860124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic load determines atrophy in hand cortico-striatal pathways in presymptomatic Huntington's disease.
    Hong Y; O'Donnell LJ; Savadjiev P; Zhang F; Wassermann D; Pasternak O; Johnson H; Paulsen J; Vonsattel JP; Makris N; Westin CF; Rathi Y
    Hum Brain Mapp; 2018 Oct; 39(10):3871-3883. PubMed ID: 29797744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
    Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
    Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.